MapLight Therapeutics Achieves Major Milestone with IPO
MapLight Therapeutics, Inc. has recently announced a significant milestone by successfully closing its initial public offering. This culmination of efforts not only showcases the company's commitment to revolutionizing treatment options for central nervous system disorders but also highlights the robust interest from investors. The IPO involved the sale of 16,962,500 shares of common stock at $17.00 each, with an impressive $296.3 million in gross proceeds generated before expenses.
Details of the Initial Public Offering
The public offering also included the full exercise of the underwriters’ option to purchase an additional 2,212,500 shares. Alongside this offering, the company successfully executed a concurrent private placement for 476,707 shares, signaling a strong demand for MapLight's future in therapeutic development.
Market Introduction and Symbol
Starting from October 27, 2025, MapLight's shares are available for trading on the Nasdaq Global Select Market under the symbol "MPLT." This move into the public market marks a critical step in the company's strategy to expand its influence and reach within the biopharmaceutical landscape.
Recognized Underwriters Driving Success
The offering was backed by renowned firms including Morgan Stanley, Jefferies, Leerink Partners, and Stifel, acting as joint book-running managers. Their expertise and resources played a crucial role in navigating the market intricacies and ensuring a successful launch.
The Path Ahead for MapLight Therapeutics
Looking forward, MapLight aims to improve the lives of patients affected by debilitating conditions such as schizophrenia and Alzheimer's disease psychosis through its lead product candidate, ML-007C-MA. This innovative oral formulation is expected to make a significant impact in the field of psychiatry and neuroscience.
Commitment to Innovative Therapies
Founded by seasoned experts in the realms of psychiatry and neuroscience, MapLight was established with a clear mission: to address the significant scarcity of effective pharmacotherapies for patients with disorders affecting the central nervous system. This commitment is not just about business; it's about bringing hope and healing to countless individuals.
Investor Relations and Media Questions
For those interested in inquiries related to investments or media, MapLight offers dedicated channels for communication. Investors can reach out via email at investors@maplightrx.com for updates and information, while media representatives can contact the company at media@maplightrx.com to discuss coverage and collaborations.
Frequently Asked Questions
What is the main focus of MapLight Therapeutics?
MapLight Therapeutics focuses on developing innovative treatment options for central nervous system disorders.
How many shares were initially offered by MapLight?
The company offered a total of 16,962,500 shares in its initial public offering.
What is the stock symbol for MapLight Therapeutics?
MapLight Therapeutics trades on the Nasdaq under the symbol "MPLT."
Who were the underwriters for the IPO?
The underwriters for the IPO included Morgan Stanley, Jefferies, Leerink Partners, and Stifel.
How can I get the prospectus for the MapLight offering?
Copies of the final prospectus can be obtained from the underwriters or by contacting their respective offices directly.
